

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*



## **APPOINTMENT OF INDEPENDENT NON-EXECUTIVE DIRECTOR AND CHANGE IN COMPOSITION OF BOARD COMMITTEES**

The board of directors (the “**Board**”) of Ocumention Therapeutics (the “**Company**”) is pleased to announce that Mr. Zhenyu ZHANG (張振宇) (“**Mr. Zhang**”) has been appointed as an independent non-executive director, the chairman of the remuneration committee and a member of the nomination committee and audit committee of the Company with effect from April 8, 2022.

The biographical details of Mr. Zhang are as follows:

Mr. Zhang, aged 46, has more than 20 years of experience in legal and corporate compliance practice. He currently serves as the vice president responsible for legal, compliance and governmental affairs of Greater China region for The a2 Milk Company Limited, a public company dual listed on the New Zealand’s Exchange (stock code: ATM) and the Australian Securities Exchange (stock code: A2M), respectively. From October 2012 to February 2019, Mr. Zhang served as the vice president responsible for legal, compliance and governmental affairs, and the general counsel as well as the chief compliance officer of Asia-Pacific region for Thermo Fisher Scientific Inc, a company whose securities are listed on the New York Stock Exchange (ticker symbol: TMO). From March 2011 to October 2012, he served as the senior legal counsel of merger and acquisition of Asia-Pacific region for United Technologies Corporation. From April 2008 to March 2011, Mr. Zhang served as a legal counsel and the chief compliance officer of Great China region for Sandoz AG, a company incorporated in Switzerland and a global research-based pharmaceutical and nutrition group. Prior to serving at Sandoz AG, Mr. Zhang has consecutively acted as an in-house legal counsel for TOM Group Limited, Sony Music Entertainment China Ltd. and Shanghai Huahong (Group) Co., Ltd. (上海華虹(集團)有限公司). Mr. Zhang has been an independent non-executive director of TANSI Global Food Group Co., Ltd (國際天食集團有限公司), a company whose shares are listed on The Stock Exchange of Hong Kong Limited (the “**Stock Exchange**”) (stock code: 3666), since May 2019.

Mr. Zhang obtained a bachelor’s degree in law from East China University of Political Science and Law (華東政法大學) in 1998 and was awarded with a diploma in Beijing International MBA from Peking University in 2010.

Mr. Zhang will enter into a service agreement with the Company with an initial term of three years commencing from April 8, 2022, which is subject to retirement by rotation and re-election at the annual general meeting of the Company pursuant to the articles of association of the Company, or vacation from office pursuant to any applicable laws from time to time. He shall hold office as an independent non-executive director of the Company only until the next annual general meeting of the Company, and shall be eligible for re-election in accordance with the articles of association of the Company. Mr. Zhang will be entitled to an annual remuneration of HK\$200,000 for his term of appointment, which is determined with reference to his duties and responsibilities and prevailing market rate.

Save as disclosed above, Mr. Zhang does not hold any other position with the Company or its subsidiaries, nor does he have any relationship with any Directors, senior management, substantial shareholder or controlling shareholders (as defined in the Rules Governing the Listing of Securities on the Stock Exchange (the “**Listing Rules**”)) of the Company.

Save as disclosed above, Mr. Zhang did not held any directorship in any public companies the securities of which are listed on any securities market in Hong Kong or overseas in the last three years and does not have any other major appointments and professional qualifications. Mr. Zhang does not have any interest in any shares or underlying shares of the Company within the meaning of Part XV of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong).

Save as disclosed above, there is no other information relating to the appointment of Mr. Zhang that need to be disclosed pursuant to Rules 13.51(2)(h) to (v) of the Listing Rules or need to be brought to the attention of the shareholders of the Company.

The Board would like to extend its warmest welcome to Mr. Zhang for his appointment to the Board.

## **COMPLIANCE OF LISTING RULES**

Reference is made to the announcement of the Company dated March 31, 2022 in relation to the passing away of an independent non-executive director of the Company.

Following the appointment of Mr. Zhang with effect from April 8, 2022, the Company has fully complied with the requirements as set out in Rules 3.10(1), 3.10A, 3.21, 3.25 and 3.27A of the Listing Rules.

By order of the Board  
**Ocumension Therapeutics**  
**Dr. Lian Yong CHEN**  
*Chairman and Non-executive Director*

Hong Kong, April 8, 2022

*As of the date of this announcement, the Board comprises Mr. Ye LIU and Dr. Zhaopeng HU as executive directors, Dr. Lian Yong CHEN, Dr. Wei LI, Mr. Yanling CAO and Ms. Yumeng WANG as non-executive directors, and Mr. Ting Yuk Anthony WU, Mr. Yiran HUANG and Mr. Zhenyu ZHANG as independent non-executive directors.*